[Israel, 30 November, 2023]GrayMatters Health (GMH), one of the portfolio companies of our subsidiary Corundum Neuroscience,formerly Joy Ventures, and an Israeli developer of digital self-neuromodulation therapies for mental disorders, announced that the Ministry of Health in Israel granted approval for marketing its flagship product, Prism for PTSD, the first non-invasive, self-neuromodulation adjunct digital therapy for post-traumatic stress disorder.

It is another remarkable accomplishment followed by the U.S. Food and Drug Administration (FDA) granting 510(k) Clearance in March 2023.

Furthermore, GMH was named the Prix Galien USA Best Startup 2023 winner, a prestigious U.S. award given to companies that have made noteworthy contribution in the field of life sciences. Stay tuned for more updates.

Learn more by visiting here.